Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can magnetic waves tame autoimmune disease? new trial begins

NCT ID NCT07221565

Disease control Sponsor: Truway Health, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a non-invasive device that uses low-frequency electromagnetic fields to improve communication between immune cells. 120 adults with lupus, rheumatoid arthritis, or multiple sclerosis will receive either active or sham sessions three times a week for 12 weeks. The goal is to see if this approach can reduce flare-ups and symptoms safely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Low-Frequency Electromagnetic Resonance Therapy (LF-EMR) device
What this could lead to
If it works, this could offer a non-invasive, drug-free way to reduce autoimmune flare-ups and improve symptom control for conditions like lupus, rheumatoid arthritis, and multiple sclerosis.
What could go wrong
This is an early-phase trial with only 120 participants, so results may not apply to everyone. The treatment is experimental, and its effectiveness and safety are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2034

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or female participants aged 18-70 years. 2. Clinical diagnosis of a systemic autoimmune disorder (e.g., systemic lupus erythematosus, rheumatoid arthritis, or multiple sclerosis) confirmed for at least 12 months. 3. Stable disease-modifying therapy or corticosteroid regimen for at least 8 weeks prior to enrollment. 4. Willingness to maintain current medication schedule for the duration of the study. 5. Ability to provide written informed consent and comply with study procedures. 6. Access to stable internet or smartphone connection for digital consent verification and symptom tracking. Exclusion Criteria: 1. Presence of an implanted medical or electronic device (e.g., pacemaker, defibrillator, deep brain stimulator). 2. Pregnancy or lactation. 3. Active infection, malignancy, or significant hepatic, renal, or cardiovascular disease. 4. Known photosensitivity, seizure disorder, or history of uncontrolled epilepsy. 5. Prior participation in any electromagnetic or quantum resonance study within the past 6 months. 6. Use of biologic or investigational therapy initiated within the previous 3 months. 7. Inability to attend at least 80% of treatment sessions or follow-up visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Autoimmune diseases are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

autoimmune disease immune system disorder multiple sclerosis rheumatoid arthritis systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Autoimmune diseases Chronic inflammatory syndromes Immune dysregulation Multiple sclerosis Rheumatoid arthritis Systemic lupus erythematosus

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)

    New York, New York, 10016, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.